Company: VRCA
Filing Date: 2025-06-05
Form Type: 8-K
Source: 0001193125-25-135949
Chunk: 1

Company: Verrica Pharmaceuticals Inc.
Filing Date: 2025-06-05
Form: 8-K
Item: Item 5.07
Chunk 1
---
Proposal No. 4: Approval of a series of alternate amendments to the Company’s Amended and Restated Certificate of Incorporation to effect, at the option of the Board of Directors, a reverse stock split of the Company’s common stock at a reverse stock split ratio ranging from 1-for-10to1-for-30, inclusive, with the effectiveness of one of such amendments and the abandonment of the other amendments, or the abandonment of all amendments, to be determined by the Board of Directors, in its sole discretion, prior to the date of the 2026 Annual Meeting of Stockholders. The votes were cast as follows:

                                                                                                                     Votes For                      Votes Against                     Abstained               
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Approval of series of alternate amendments to the Company’s Amended and Restated Certificate of Incorporation                     80,455,548                         2,786,227                     184,981  

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                          Verrica Pharmaceuticals Inc.     
  Date: June 5, 2025      /s/ John J. Kirby                
                          John J. Kirby                    
                          Interim Chief Financial Officer